Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02851173 · ClinicalTrials.gov registry record · Phase 2

Cognitive Enhancement Through Transcranial Laser Therapy

A Phase 2 study, sponsored by University of Texas at Austin.

Completed
Registry status
Phase 2
Development phase
91
Enrollment target

NCT02851173: Completed Phase 2 study, sponsored by University of Texas at Austin.

NCT02851173 is a Phase 2 study that has completed, run by University of Texas at Austin. The registered enrollment target is 91 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02851173, a Phase 2 study, has completed, sponsored by University of Texas at Austin.

COMPLETED
Registry status
Phase 2
Development phase
91 participants
Enrollment target

Study Summary

This is a mechanism-driven translational project to test the efficacy of transcranial low-level light/laser therapy (LLLT), for enhancing cognitive function in middle-aged and older adults and participants with Mild Cognitive Impairment.

Primary Outcome

The psychomotor vigilance task (PVT) is a sustained-attention, reaction-timed task that measures the consistency with which subjects respond to a visual stimulus.

Interventions

  • DEVICE Placebo
  • DEVICE LLLT

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2016-02-21
Est. Completion 2020-04-30
Phase Phase 2
University of Texas at Austin

257 total trials

What the finished NCT02851173 record still lists

NCT02851173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02851173 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02851173 about?

NCT02851173 is a clinical study titled "Cognitive Enhancement Through Transcranial Laser Therapy". This is a mechanism-driven translational project to test the efficacy of transcranial low-level light/laser therapy (LLLT), for enhancing cognitive function in middle-aged and older adults and participants with Mild Cognitive Impairment.

What is the current status of trial NCT02851173?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2016-02-21. Estimated completion is 2020-04-30.

What interventions are being tested in trial NCT02851173?

The interventions under investigation include: Placebo (DEVICE), LLLT (DEVICE).

Who is sponsoring clinical trial NCT02851173?

This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02851173's enrollment target sits among peer trials

91 771st of 2000 higher than 1,229 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02671448 · 91 participants · NA

    Pilot Trial of Homebound Stem Cell Transplantation

  • NCT04835857 · 91 participants

    Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices

  • NCT05184842 · 91 participants · Phase 2

    Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

  • NCT05685173 · 91 participants · Phase 1

    A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02851173, the US trial registry maintained by the National Library of Medicine. NCT02851173 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.